Narcolepsy Type 1

Neurology·MeSH: Narcolepsy

Prevalence

30.0 / 100K

12 drugs in development·5 companies·13 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
ALKS 2680	Alkermes plc. (ALKS)
tak-360	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-861	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-861	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-861	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(1)

Drug	Company
ORX750	Centessa Pharmaceuticals plc (CNTA)

Phase 1(2)

Drug	Company
bupropion	VERTEX PHARMACEUTICALS INC / MA (VRTX)
vx-433	VERTEX PHARMACEUTICALS INC / MA (VRTX)

Phase 2/Phase 3(3)

Drug	Company
Alixorexton (ALKS 2680)	Alkermes plc. (ALKS)
cleminorexton	Centessa Pharmaceuticals plc (CNTA)
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

BioSniper tracks 12 drugs in development for Narcolepsy Type 1 across 5 companies.

There are 13 clinical trials targeting Narcolepsy Type 1 tracked by BioSniper.

The estimated prevalence of Narcolepsy Type 1 is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.